Acta Epileptologica最新文献

{"title":"Predictive value of peripheral blood inflammatory markers for epilepsy occurrence in traumatic brain injury patients.","authors":"Sheng-Xue Wang, Qiang Zi, Yu-Xuan Li, Wang Guo, Yu-Hao Chu, Xue-Ping Yang, Yun Li","doi":"10.1186/s42494-025-00226-2","DOIUrl":"10.1186/s42494-025-00226-2","url":null,"abstract":"<p><strong>Background: </strong>Post-traumatic epilepsy (PTE) is characterised by recurrent epileptic seizures following traumatic brain injury (TBI). PTE has a high incidence and leads to significant disability rates, posing a substantial socioeconomic burden. This study aimed to evaluate the predictive value of peripheral blood inflammatory markers-including neutrophils, lymphocytes, platelets, the neutrophil-to-lymphocyte ratio (NLR), and the platelet-to-lymphocyte ratio (PLR)-for seizure risk in patients with TBI.</p><p><strong>Methods: </strong>This investigation involved the enrollment of patients admitted to the Department of Neurology/Surgery at the First Affiliated Hospital of Dali University in Yunnan Province, China, spanning the period from January 2020 to May 2023. Our cohort comprised 138 individuals with PTE, 150 with TBI, 142 with epilepsy of unknown origin, and 130 healthy controls (HC). We retrospectively analysed demographic characteristics and peripheral blood cell inflammation markers for all participants.</p><p><strong>Results: </strong>1. In the PTE group, both neutrophil count and NLR exhibited higher levels compared to the TBI group, the epilepsy of unknown origin group, and the HC group. Conversely, the lymphocyte count, platelet count, and PLR in the group were lower in contrast to the TBI group, the epilepsy of unknown origin group, and the HC group. 2. Neutrophil count, lymphocyte count, platelet count, NLR, and PLR were significantly different between the PTE and TBI, PTE and HC groups (P < 0.05). Marked distinctions were detected in neutrophil count, platelet count, NLR, and PLR between the PTE group and the epilepsy of unknown origin group (P < 0.05). 3. Furthermore, our multivariate linear regression analysis unveiled that the TBI site (temporal lobe) (P < 0.05), the severity of TBI (mild, moderate, severe) (P < 0.05), and surgical intervention (P < 0.05) are the risk factors affecting the peripheral blood inflammation indicators. 4. Finally, the ROC analysis produced an AUC of 0.908 for neutrophil levels (cut-off: 4.05, sensitivity: 0.783, specificity: 0.992) and an AUC of 0.960 for NLR (cut-off: 2.945, sensitivity: 0.797, specificity: 0.992).</p><p><strong>Conclusions: </strong>Both neutrophil count and the NLR were significantly increased in the PTE group, suggesting that these parameters may serve as predictors of epilepsy development in TBI patients.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"36"},"PeriodicalIF":1.2,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144508719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minocycline in chronic management of febrile infection-related epilepsy syndrome (FIRES): a case series and literature review of treatment strategies.","authors":"Lanlan Feng, Hui Li, Lei Ma, Mengmeng Hu, Bo Hui, Zhongqing Sun, Xiaomu Wang, Yuanyuan Wang, Wen Jiang","doi":"10.1186/s42494-025-00224-4","DOIUrl":"10.1186/s42494-025-00224-4","url":null,"abstract":"<p><p>The effectiveness of treatment for the chronic phase of febrile infection-related epilepsy syndrome (FIRES) remains uncertain. This study aimed to evaluate the therapeutic efficacy of minocycline in patients with chronic FIRES who had a poor response to conventional antiseizure medications. Three patients received 100 mg of minocycline (100 mg twice daily for 12 weeks), with effectiveness assessed based on seizure frequency, duration, type, and quality of life (using the quality of life in epilepsy-31, QOLIE-31), alongside adverse event monitoring. Results showed that one patient (Patient 3) exhibited a significant reduction in seizure duration and improved QOLIE-31 scores, with focal seizures being the only type observed after treatment. However, there was no statistically significant change in overall seizure frequency among the three patients. Additionally, a short literature review was conducted to explore various management strategies for chronic FIRES, including IL-1 receptor antagonist (anakinra) and IL-6 receptor antagonist (tocilizumab), centro-median thalamic nuclei deep brain stimulation, cannabidiol, responsive neurostimulation, intrathecal dexamethasone, ketogenic diet, and vagus nerve stimulation. In conclusion, considering the existing research on the etiological mechanisms of FIRES and based on our preliminary findings on the anti-inflammatory and antiepileptic properties of minocycline, early initiation of minocycline therapy in the chronic phase of FIRES should be explored further.Trial registrationClinicaltrials.gov (NCT05958069, retrospectively registered 22 July 2023).</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"35"},"PeriodicalIF":1.2,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type I Sialidosis in a Chinese family: a case report and literature review.","authors":"Xia Zhou, Shengyou Su, Shenghua Li, ZuFang Yi, Liling Feng, Junyi Chen, Binglin Fan","doi":"10.1186/s42494-025-00225-3","DOIUrl":"10.1186/s42494-025-00225-3","url":null,"abstract":"<p><strong>Background: </strong>Sialidosis is an autosomal recessive hereditary disease characterized by the mutation of neuraminidase-1 (NEU1) gene, resulting in decreased activity of α-N-acetylneuraminidase. This leads to metabolic abnormalities in various organs. Sialidosis is classified into two distinct clinical phenotypes, type I and type II, based on the age of onset and severity of clinical manifestations.</p><p><strong>Case presentation: </strong>Here, we report a case involving a patient and his two sisters, all of whom showed seizures and ataxia during adolescence, with progressively worsening symptoms. Prior to admission, none of the patients had received a systemic diagnosis or treatment. The whole exome sequencing identified a homozygous NEU1 mutation (NM_000434.3:c.544A > G [p.Ser182Gly]) in all three siblings. Their parents and children, who were asymptomatic, were found to be heterozygous carriers. The three patients were ultimately diagnosed with type I sialidosis and treated with antiseizure medications, but they continued to experience recurrent seizures.</p><p><strong>Conclusions: </strong>This case report enhances our understanding of sialidosis, particularly in patients presenting with seizures and ataxia. Furthermore, the gene sequencing is a crucial tool for confirming the diagnosis of sialidosis and provides a valuable approach for genetic counseling in affected families.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"34"},"PeriodicalIF":1.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic changes in comorbid conditions following vagus nerve stimulation for epilepsy.","authors":"Deng Chen, Lina Zhu, Ling Liu, Dong Zhou, Xintong Wu","doi":"10.1186/s42494-025-00222-6","DOIUrl":"10.1186/s42494-025-00222-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Vagus nerve stimulation (VNS) has been widely used in the clinical treatment of epilepsy, while its effects on comorbidities in epilepsy remain incompletely elucidated. This study aimed to evaluate the impact of VNS on comorbidities and quality of life in adult patients with epilepsy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A longitudinal, multicenter cohort study was conducted from 2021 to 2024 among adult patients with epilepsy who underwent VNS implantation. We enrolled 128 participants from 83 hospitals. The inclusion criteria were patients over 18 years old, diagnosed with epilepsy according to the 2014 International League Against Epilepsy guidelines, and having complete data from at least two follow-up visits. Standard assessment tools, including diagnosis according to International Classification of Diseases, 10th Edition (ICD-10), Neurological Disorders Depression Inventory for Epilepsy (NDDI-E), Generalized Anxiexy Disorde-7 (GAD-7), Pittsburgh Sleep Quality Index (PSQI), and Quality of Life in Epilepsy-31 (QOLIE-31) were used to evaluate comorbidities and quality of life. Statistical analysis was performed using SPSS 26.0. The major clinical measurements were changes in the scales above before and after VNS implantation during follow-up. Generalized estimation model was applied to illustrate the effect over time an its relation to seizure control.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 113 participants met the inclusion criteria. Baseline characteristics were comparable between the comorbidity and non-comorbidity groups in terms of gender, seizure onset, age at VNS implantation, seizure types, or the number of antiseizure medications used. Significant improvements were observed from the implantation to the end of follow-up. The PSQI score decreased from 5.43 ± 3.60 to 4.44 ± 3.14 (P &lt; 0.01), indicating better sleep quality. Depressive symptoms (NDDI-E) and anxiety symptoms (GAD-7) decreased significantly, with scores dropping from 6.49 ± 4.67 to 4.83 ± 4.37 (P &lt; 0.01) and from 7.15 ± 5.06 to 4.95 ± 3.69 (P &lt; 0.01), respectively. The QOLIE-31 score increased from 54.40 ± 15.70 to 61.33 ± 16.19 (P &lt; 0.01), suggesting improved quality of life. Further analysis indicated that in the early second postoperative follow-up (1 month after implantation), the scales had already improved significantly (P &lt; 0.001 for PSQI and QOLIE-31, P = 0.006 for NDDI-E and GAD-7). We did not find any statistically significant difference between patients with comorbidity and those without on the efficacy of any scales in this study. The efficacy of VNS on the four scales above was related to follow-up time, with a slightly rebound at the last two follow-ups. The NDDI-E as well as the GAD-7 scores were related to better seizure control according to the GEE model. Higher stimulation currents over 1 mA did not improve the efficacy of VNS on the comorbid conditions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;VNS implantation significantly improv","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"33"},"PeriodicalIF":1.2,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12123979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel c.116 - 117 del variant in Unverricht-Lundborg disease: first ULD report in large Chinese population and review of the pathogenetic variants in CSTB gene.","authors":"Pu Miao, Yao Ding, Zhidong Cen, Yulan Chen, Wei Luo, Baorong Zhang, Zhiying Wu, Meiping Ding, Shuang Wang","doi":"10.1186/s42494-025-00216-4","DOIUrl":"10.1186/s42494-025-00216-4","url":null,"abstract":"<p><strong>Background: </strong>Unverricht-Lundborg disease (ULD) is a rare autosomal recessive neurodegenerative disorder, often caused by biallelic promoter expansions of CSTB gene or, more rarely by point/indel variants. The best-known area for ULD are the shores of the Baltic and Mediterranean Sea and few cases have been recorded from Asia.</p><p><strong>Case presentation: </strong>In this report, we present the first case of a Chinese patient with ULD. The patient was a 21-year-old female with normal cognitive function. She developed nocturnal bilateral tonic-clonic seizures (BTCS) at age 8, with subsequent onset of myoclonic jerks along with ataxia at age 12. Myoclonic jerks were triggered by flashing lights and during menstrual periods. EEG recording showed multifocal spikes and sharp-waves, predominantly in bilateral occipital regions. Genetic testing revealed heterozygous compound variants for a novel indel variant (c.116 - 117 delAG) and the repeat expansion of CSTB gene. The refractory BTCS and myoclonic jerks showed remarkable response to low-dose (2 mg/day) perampanel treatment. After 24 months of follow-up, the patient remained seizure-free, but her myoclonic jerks recurred, which could be reduced by increasing the dosage of perampanel.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first report of ULD in the large Chinese population. By comparison with homozygous promoter expansions, we found an earlier age of first symptom onset and more refractory BTCS of ULD patients with compound or homozygous point/indel variants.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"32"},"PeriodicalIF":1.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144181856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database.","authors":"Jianxiong Gui, Lingman Wang, Linxue Meng, Xiaofang Zhang, Jiannan Ma, Li Jiang","doi":"10.1186/s42494-025-00223-5","DOIUrl":"10.1186/s42494-025-00223-5","url":null,"abstract":"<p><strong>Background: </strong>Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.</p><p><strong>Methods: </strong>This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).</p><p><strong>Results: </strong>A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.</p><p><strong>Conclusions: </strong>This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"31"},"PeriodicalIF":1.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144128991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seizure frequency, APOE ε4, and cognitive function in older people with epilepsy.","authors":"Yiling Chen, Zhenxu Xiao, Xiaowen Zhou, Saineng Ding, Luxin Jiang, Qianhua Zhao, Ding Ding, Jianhong Wang, Guoxing Zhu","doi":"10.1186/s42494-025-00213-7","DOIUrl":"10.1186/s42494-025-00213-7","url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment represents a major comorbidity among older adults with epilepsy. This study aimed to explore the association between the apolipoprotein E (APOE) ε4 allele and cognitive function in older people with epilepsy.</p><p><strong>Methods: </strong>People with epilepsy aged ≥ 50 years were enrolled at an outpatient clinic of epilepsy from November 2019 to July 2024. Blood samples were collected for APOE genotyping. Participants were categorized into two groups based on the presence of the APOE ε4 allele: APOE ε4 (+/-). Cognitive function was assessed using a battery with neuropsychological tests. Based on Mini-Mental State Examination (MMSE) scores, participants were defined as unimpaired cognition (UC) (MMSE ≥ 27) and cognitive impairment (CI) (MMSE < 27). Seizure frequency was categorized into low (≤ 3/year) and high (> 3/year) groups. Multivariate logistic regression analysis and general linear models were employed to identify factors associated with cognitive function.</p><p><strong>Results: </strong>Among 110 participants, 51 (46.4%) were defined as CI. Compared with UC group, the CI group was older (65.1 ± 7.6 vs 60.8 ± 6.8 years, P = 0.002), with lower educational level (9.0 [7.0, 11.0] vs 12.0 [9.0, 13.0] years, P < 0.001), and higher seizure frequency (12.0 [1.0, 24.0] vs 1.0 [0.0, 12.0] times/year, P = 0.005). High seizure frequency (OR = 3.94, 95% CI [1.34, 11.61], P = 0.013) and more APOE ε4 alleles (OR = 3.28, 95% CI [1.09, 9.83], P = 0.034) were risk factors for CI. An interactive effect between the number of APOE ε4 alleles and seizure frequency was observed (P = 0.002). Compared to participants with APOE ε4 (-) and low seizure frequency, those with APOE ε4 (-) and high seizure frequency showed a threefold risk of CI (OR = 3.34, 95% CI [0.99, 11.25], P = 0.051), while those with APOE ε4 (+) and high frequency demonstrated the highest risk of CI (OR = 10.53, 95% CI [1.75, 63.47], P = 0.010).</p><p><strong>Conclusions: </strong>The synergistic effect of APOE ε4 allele and seizure frequency on cognitive function suggested their importance in clinical assessments and therapeutic approaches in managing older people with epilepsy.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"30"},"PeriodicalIF":1.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144129048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress on epilepsy with myoclonic absence.","authors":"Fen Tang, Minting Li, Liangmin Liu, Xuemei Wang, Bing Qin","doi":"10.1186/s42494-025-00218-2","DOIUrl":"10.1186/s42494-025-00218-2","url":null,"abstract":"<p><p>Epilepsy with myoclonic absence (EMA) is a rare childhood-onset generalized epilepsy syndrome characterized by myoclonic absence seizures. First discovered by Tassinari et al. in 1969, EMA has been extensively studied by researchers from all over the world. This review synthesizes recent studies on EMA, covering its discovery history, classification, epidemiology, pathophysiology, etiology, clinical manifestations, diagnosis and differential diagnosis, treatment, prognosis and evolution, and especially discusses the etiology and pathophysiology mechanism, to help clinicians understand this relatively rare epilepsy syndrome, reduce the rate of missed diagnosis and misdiagnosis, and effectively guide treatment to alleviate the long-term cognitive impairment in affected individuals.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"29"},"PeriodicalIF":1.2,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12082880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144086400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of vagus nerve stimulation in patients with drug-resistant epilepsy: a single center experience.","authors":"Ebtehal Alwazna, Jamal Abdullah, Hanin Alsini, Marahib Alshahrani, Wafa Aldhafeeri, Alawi Al-Attas, Abeer Alshaikh, Mashael Alanazi, Hamoud Alsahli, Mohammed Alshahrani, Shatha Alshafi, Brahim Tabarki, Abdulrahman Nazer, Sonia Khan","doi":"10.1186/s42494-025-00215-5","DOIUrl":"https://doi.org/10.1186/s42494-025-00215-5","url":null,"abstract":"<p><strong>Background: </strong>Drug-resistant epilepsy (DRE) exerts substantial clinical, humanistic and economic burdens on patients, their families and the healthcare system. Vagus nerve stimulation (VNS) has been extensively tested in clinical trial settings to decrease the frequency of seizures in patients with DRE who are not candidates for surgery; the results indicate promising efficacy and a well-tolerated safety profile. However, real-world evidence is still lacking. This retrospective study evaluated the safety and efficacy of VNS in patients with DRE.</p><p><strong>Methods: </strong>The current study was a retrospective chart review of the medical records of children and adults with DRE treated with VNS between December 2006 and November 2022. The primary outcome of the present study was the percentage of patients who experienced a reduction in seizure frequency of more than 50% compared with the frequency at baseline (the period before VNS device insertion).</p><p><strong>Results: </strong>A total of 103 patients were included. The percentage of patients who achieved a reduction of more than 50% in seizure frequency was 23% at six months, 36% at 12 months, 65% at 18 months, and 72% at 24 months. Similarly, the percentage of patients with complete resolution of interictal epileptiform discharges (IEDs) increased from 30% at six months to 60% after 24 months. The overall Quality of Life in Epilepsy (QOLIE-31) score at the end of follow-up was 39.46 ± 13.68 points. Two patients (1.9%) reported experiencing side effects at the end of follow-up.</p><p><strong>Conclusions: </strong>VNS implementation led to a significant reduction in the seizure frequency and resolution of IEDs, with a well-tolerated safety profile. The findings highlight the potential role of VNS in managing DRE and warrant its consideration for treating patients with DRE.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"28"},"PeriodicalIF":1.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: late adverse reactions in an epilepsy patient on combination therapy with valproate and lamotrigine.","authors":"Hui Sang, Liqiao Zhao, Yanhua Zhang, Xiaolong Wang, Xiaodong Zhang","doi":"10.1186/s42494-025-00217-3","DOIUrl":"https://doi.org/10.1186/s42494-025-00217-3","url":null,"abstract":"<p><strong>Background: </strong>Late adverse reactions associated with the combined therapy of valproate and lamotrigine are infrequently documented within the Chinese population.</p><p><strong>Case presentation: </strong>This case report describes a 54-year-old female patient who developed adverse reactions following long-term therapy with valproate and lamotrigine, with symptoms emerging five months after the final adjustment of her antiseizure regimen. The patient presented with symptoms of dizziness, ataxia, nystagmus, and postural tremors. Following blood drug concentration monitoring and subsequent minor dosage adjustments to the antiseizure regimen without medication withdrawal, the patient's symptoms were successfully resolved.</p><p><strong>Conclusions: </strong>This article underscores the importance of vigilance among clinicians regarding the potential for late adverse reactions and advocates for the proactive monitoring of blood drug concentrations.</p>","PeriodicalId":33628,"journal":{"name":"Acta Epileptologica","volume":"7 1","pages":"27"},"PeriodicalIF":1.2,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}